TRDA

SEC source: 0001209191-22-030168 · doc4.xml · nonDerivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 354,674

F8 · price: The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $5.85 to $6.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F2 · ownership.nature: After giving effect to the transaction herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an assetbased management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-22-030168 · doc4.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,391,686

F7 · price: The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $5.70 to $6.04, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an assetbased management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001209191-22-030168 · doc4.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 351,020

F7 · price: The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $5.70 to $6.04, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F2 · ownership.nature: After giving effect to the transaction herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an assetbased management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-22-030168 · doc4.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,390,994

F6 · price: The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $5.86 to $6.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an assetbased management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001209191-22-030168 · doc4.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 350,936

F6 · price: The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $5.86 to $6.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F2 · ownership.nature: After giving effect to the transaction herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an assetbased management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-22-030168 · doc4.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,374,493

F1 · price: The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Entrada Therapeutics, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $5.65 to $5.98, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an assetbased management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001209191-22-030168 · doc4.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · 10% owner

BAKER JULIAN · CIK 0001087939 · 10% owner

BAKER FELIX · CIK 0001087940 · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 348,926

F1 · price: The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Entrada Therapeutics, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $5.65 to $5.98, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F2 · ownership.nature: After giving effect to the transaction herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an assetbased management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001104659-22-030009 · tm228284-5_4seq1.xml · derivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,575

Underlying: Common Stock · 67,575 shares

Expires 2032-03-01

F2 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

SEC source: 0001104659-22-030009 · tm228284-5_4seq1.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,607

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001104659-22-030008 · tm228284-4_4seq1.xml · derivative · entry 2

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,525

Underlying: Common stock · 69,525 shares

Expires 2032-03-01

F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

SEC source: 0001104659-22-030008 · tm228284-4_4seq1.xml · nonDerivative · entry 1

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,350

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F2 · balance_after: Consists of (i) 118,836 shares of common stock, (ii) 25,926 shares of restricted common stock issued upon early exercise of stock options, and (iii) 11,588 RSUs reported in this transaction.

SEC source: 0001104659-22-030005 · tm228284-3_4seq1.xml · derivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,063

Underlying: Common stock · 62,063 shares

Expires 2032-03-01

F2 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

SEC source: 0001104659-22-030005 · tm228284-3_4seq1.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,544

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001104659-22-030004 · tm228284-2_4seq1.xml · derivative · entry 2

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,038

Underlying: Common stock · 66,038 shares

Expires 2032-03-01

F2 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

SEC source: 0001104659-22-030004 · tm228284-2_4seq1.xml · nonDerivative · entry 1

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,541

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001104659-22-030002 · tm228284d1_4seq1.xml · derivative · entry 2

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,500

Underlying: Common stock · 181,500 shares

Expires 2032-03-01

F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.

SEC source: 0001104659-22-030002 · tm228284d1_4seq1.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,710

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F2 · balance_after: Consists of (i) 172,467 shares of common stock (ii) 11,993 shares of restricted common stock issued upon early exercise of stock options, and (iii) 30,250 RSUs reported in this transaction.

SEC source: 0001104659-22-004980 · tm223204-1_4seq1.xml · derivative · entry 2

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,989

Underlying: Common Stock · 10,000 shares

Expires 2029-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 31, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001104659-22-004980 · tm223204-1_4seq1.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Consists of (i) 170,067 shares of common stock and (ii) 14,393 shares of restricted common stock issued upon early exercise of stock options.

SEC source: 0001104659-22-004129 · tm222967-1_4seq1.xml · nonDerivative · entry 1

Crowley John F · CIK 0001400973 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001104659-21-154295 · tm2136524-1_4seq1.xml · derivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,722

Underlying: Common Stock · 5,200 shares

Expires 2030-12-01

F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001104659-21-154295 · tm2136524-1_4seq1.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-134647 · tm2132054-1_4seq1.xml · derivative · entry 4

ROCHE HOLDING LTD · CIK 0000889131 · 10% owner

ROCHE FINANCE LTD · CIK 0001053942 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 318,140 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.

SEC source: 0001104659-21-134647 · tm2132054-1_4seq1.xml · derivative · entry 3

ROCHE HOLDING LTD · CIK 0000889131 · 10% owner

ROCHE FINANCE LTD · CIK 0001053942 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,495,385 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.

SEC source: 0001104659-21-134647 · tm2132054-1_4seq1.xml · nonDerivative · entry 2

ROCHE HOLDING LTD · CIK 0000889131 · 10% owner

ROCHE FINANCE LTD · CIK 0001053942 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,813,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.

SEC source: 0001104659-21-134647 · tm2132054-1_4seq1.xml · nonDerivative · entry 1

ROCHE HOLDING LTD · CIK 0000889131 · 10% owner

ROCHE FINANCE LTD · CIK 0001053942 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,495,385

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · ownership.nature: Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.

SEC source: 0001209191-21-062982 · doc4.xml · derivative · entry 5

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

EVNIN LUKE · CIK 0001134657 · 10% owner

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 509,024 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F5 · ownership.nature: The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018.

SEC source: 0001209191-21-062982 · doc4.xml · derivative · entry 4

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

EVNIN LUKE · CIK 0001134657 · 10% owner

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,816,760 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · ownership.nature: The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. ..

SEC source: 0001209191-21-062982 · doc4.xml · nonDerivative · entry 3

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

EVNIN LUKE · CIK 0001134657 · 10% owner

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,425,784

F7 · shares: The shares were purchased as follows: 45,408 by BV 2014, 3,029 by BV 2014(B), 1,563 by AM BV2014, 46,603 by BV 2018, 2,477 by BV 2018(B) and 920 by AM BV2018.

F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F8 · ownership.nature: The shares are held as follows: 2,009,676 by BV 2014, 134,042 by BV 2014(B), 69,174 by AM BV2014, 2,062,562 by BV 2018, 109,623 by BV 2018(B) and 40,707 by AM BV2018.

SEC source: 0001209191-21-062982 · doc4.xml · nonDerivative · entry 2

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

EVNIN LUKE · CIK 0001134657 · 10% owner

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,325,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018.

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F6 · ownership.nature: The shares are held as follows: 1,964,268 by BV 2014, 131,013 by BV 2014(B), 67,611 by AM BV2014, 2,015,959 by BV 2018, 107,146 by BV 2018(B) and 39,787 by AM BV2018.

SEC source: 0001209191-21-062982 · doc4.xml · nonDerivative · entry 1

MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner

EVNIN LUKE · CIK 0001134657 · 10% owner

GADICKE ANSBERT · CIK 0001134655 · 10% owner

MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner

MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner

MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner

MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner

MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,816,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. ..

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F3 · ownership.nature: The shares are held as follows: 1,733,129 by BV 2014, 115,596 by BV 2014(B), 59,655 by AM BV2014, 1,778,737 by BV 2018, 94,538 by BV 2018(B) and 35,105 by AM BV2018.

F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001209191-21-062983 · doc4.xml · derivative · entry 5

MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner

MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner

MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 509,024 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F5 · ownership.nature: The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018.

SEC source: 0001209191-21-062983 · doc4.xml · derivative · entry 4

MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner

MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner

MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,816,760 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F2 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F1 · ownership.nature: The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. ..

SEC source: 0001209191-21-062983 · doc4.xml · nonDerivative · entry 3

MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner

MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner

MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,425,784

F7 · shares: The shares were purchased as follows: 45,408 by BV 2014, 3,029 by BV 2014(B), 1,563 by AM BV2014, 46,603 by BV 2018, 2,477 by BV 2018(B) and 920 by AM BV2018.

F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F8 · ownership.nature: The shares are held as follows: 2,009,676 by BV 2014, 134,042 by BV 2014(B), 69,174 by AM BV2014, 2,062,562 by BV 2018, 109,623 by BV 2018(B) and 40,707 by AM BV2018.

SEC source: 0001209191-21-062983 · doc4.xml · nonDerivative · entry 2

MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner

MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner

MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,325,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The shares were converted as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018.

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F6 · ownership.nature: The shares are held as follows: 1,964,268 by BV 2014, 131,013 by BV 2014(B), 67,611 by AM BV2014, 2,015,959 by BV 2018, 107,146 by BV 2018(B) and 39,787 by AM BV2018.

SEC source: 0001209191-21-062983 · doc4.xml · nonDerivative · entry 1

MPM BIOVENTURES 2018, L.P. · CIK 0001729505 · 10% owner

MPM BioVentures 2018 LLC · CIK 0001818702 · 10% owner

MPM BioVentures 2018 GP LLC · CIK 0001818701 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,816,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares were converted as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. ..

F2 · price: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

F3 · ownership.nature: The shares are held as follows: 1,733,129 by BV 2014, 115,596 by BV 2014(B), 59,655 by AM BV2014, 1,778,737 by BV 2018, 94,538 by BV 2018(B) and 35,105 by AM BV2018.

F4 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001209191-21-063040 · doc4.xml · derivative · entry 11

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 318,140 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · derivative · entry 10

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 254,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · derivative · entry 9

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 564,217 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · derivative · entry 8

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,371,739 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · derivative · entry 7

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 318,616 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · nonDerivative · entry 6

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,132,357

SEC source: 0001209191-21-063040 · doc4.xml · nonDerivative · entry 5

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 882,357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · nonDerivative · entry 4

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,276,022

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · nonDerivative · entry 3

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 564,217

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F3 · ownership.nature: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · nonDerivative · entry 2

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,021,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001209191-21-063040 · doc4.xml · nonDerivative · entry 1

5AM Ventures V, L.P. · CIK 0001674324 · 10% owner

5AM Partners V, LLC · CIK 0001791889 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 649,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series Seed Preferred Stock, Series A Preferred Stock and Series B Preferred Stock automatically converted into 0.1382 shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

SEC source: 0001104659-21-134623 · tm2131859-1_4seq1.xml · derivative · entry 3

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Redmile Biopharma Investments III, L.P. · CIK 0001838746 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 954,420 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.

F1 · derivative.underlying_shares: The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-21-134623 · tm2131859-1_4seq1.xml · nonDerivative · entry 2

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Redmile Biopharma Investments III, L.P. · CIK 0001838746 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,954,420

F3 · balance_after: Reflects number of shares owned as of November 2, 2021.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-21-134623 · tm2131859-1_4seq1.xml · nonDerivative · entry 1

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Redmile Biopharma Investments III, L.P. · CIK 0001838746 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 954,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.

F1 · price: The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.